Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24307964 | 1.00 | EPHX1 (0.48) | EPHX1SLC1A3SLC1A2SLC1A1TGM2 | |
| SCHEMBL24308004 | 0.88 | EPHX1 (0.46) | EPHX1SLC1A3SLC1A2SLC1A1TGM2 | |
| SCHEMBL24307999 | 0.86 | PSMB5 (0.48) | EPHX1SLC1A3SLC1A2SLC1A1TGM2 | |
| SCHEMBL24308331 | 0.86 | PSMB5 (0.48) | EPHX1SLC1A3SLC1A2SLC1A1TGM2 | |
| SCHEMBL24308341 | 0.85 | PSMB5 (0.48) | EPHX1SLC1A3SLC1A2SLC1A1TGM2 | |
| SCHEMBL24307962 | 0.85 | PSMB5 (0.48) | EPHX1SLC1A3SLC1A2SLC1A1TGM2 | |
| SCHEMBL24307968 | 0.83 | TGM2 (0.48) | EPHX1SLC1A3SLC1A2SLC1A1TGM2 | |
| SCHEMBL24308335 | 0.83 | TGM2 (0.48) | EPHX1SLC1A3SLC1A2SLC1A1TGM2 | |
| SCHEMBL24307998 | 0.80 | SLC1A3 (0.55) | EPHX1SLC1A3SLC1A2SLC1A1TGM2 | |
| SCHEMBL24308352 | 0.80 | SLC1A3 (0.55) | EPHX1SLC1A3SLC1A2SLC1A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-11-23 | — | — | US | disclosed |
| WO-2022075486-A1 | NOVEL BICYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374034-A1 | NOVEL BICYCLIC COMPOUNDS | NOTCH1, NOTCH2, HES1 | EPHX1 2685/4885SLC1A3 2331/4885SLC1A2 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.